Table 1.
Clinical characteristics and response of patients treated with octreotide.
| Patient | Age, years | Sex | Histological finding | Prior therapy | Best response | Time to progression, days | sstr2A IS | sstr2A ASP |
|---|---|---|---|---|---|---|---|---|
| 1 | 53 | F | Meningioma | Surgery | Stable | 194 | 3 | 4 |
| 2 | 38 | M | Atypical meningioma | Surgery | Stable | ≥6700 | 3 | 4 |
| 3 | 43 | M | Meningioma | Surgery, XRT | Stable | 125 | 2–3 | 4 |
| 4 | 64 | M | Atypical meningoma | Surgery, XRT | Stable | 118 | ||
| 5 | 38 | M | Hemangiopericytoma | Surgery, XRT | Stable | 196 | ||
| 6 | 36 | F | Meningoma | Surgery, XRT | Stable | 93 | 1–2 | 4 |
| 7 | 48 | M | Anaplastic meningioma | Surgery, XRT | Progression | 33 | … | … |
| 8 | 59 | M | Anaplastic meningoma | Surgery, XRT, BCNU | Progression | 31 | … | … |
| 9 | 52 | F | Anaplastic meningioma | Surgery, XRT | Progression | 22 | 2–3 | 4 |
| 10 | 65 | M | Anaplastic meningoma | Surgery, XRT, tamoxifen | Stable | 939 | … | … |
| 11 | 56 | M | Anaplastic meningioma | Surgery, XRT | Stable | 45 | … | … |
| 12 | 35 | M | Clear cell meningioma | Surgery, XRT, hydroxyurea | Stable | 134 | 2 | 4 |
ASP indicates area of staining positivity; BCNU indicates 1,3-bis(2-choroethyl)-1-nitrosourea; IS indicates intensity of staining; XRT indicates radiotherapy.